| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/CMAR.S58285 |
| P8608 | Fatcat ID | release_s5k4h4qf4bdi7h5ezboa5cjoku |
| P932 | PMC publication ID | 4542411 |
| P698 | PubMed publication ID | 26316817 |
| P2093 | author name string | Mauricio J Reginato | |
| Sergey V Karakashev | |||
| P2860 | cites work | Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway | Q24299670 |
| Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. | Q50649984 | ||
| Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. | Q51683888 | ||
| Hypoxia promotes nuclear translocation and transcriptional function in the oncogenic tyrosine kinase RON. | Q51718762 | ||
| Hypoxia-induced autophagy: cell death or cell survival? | Q51919982 | ||
| The ERBB network: at last, cancer therapy meets systems biology. | Q54498075 | ||
| A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study | Q71048573 | ||
| Hypoxia inhibits G1/S transition through regulation of p27 expression | Q73287965 | ||
| Aberrant type I and type III collagen gene expression in human breast cancer in vivo | Q77349737 | ||
| ERBB2 oncogene in human breast cancer and its clinical significance | Q77495138 | ||
| Overexpression of MMP-9 and HIF-1α in Breast Cancer Cells under Hypoxic Conditions | Q39716859 | ||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. | Q39765512 | ||
| Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells | Q39869337 | ||
| Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology | Q39919528 | ||
| A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth | Q39922975 | ||
| Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity | Q39958640 | ||
| Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. | Q40012178 | ||
| Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer | Q40063874 | ||
| HIF-dependent antitumorigenic effect of antioxidants in vivo | Q40085629 | ||
| A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts | Q40144642 | ||
| Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia | Q40244028 | ||
| Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation | Q40337557 | ||
| Multiple roles for the receptor tyrosine kinase axl in tumor formation | Q40360957 | ||
| Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications | Q40585883 | ||
| Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction | Q40920382 | ||
| Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors | Q43140228 | ||
| Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis | Q43569584 | ||
| Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair | Q43770342 | ||
| Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells | Q43973987 | ||
| 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. | Q44426540 | ||
| The discovery of receptor tyrosine kinases: targets for cancer therapy | Q44879898 | ||
| HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. | Q45387477 | ||
| Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. | Q45939750 | ||
| Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. | Q46698160 | ||
| Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. | Q46823917 | ||
| Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 | Q24304533 | ||
| Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer | Q24314720 | ||
| General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia | Q24315006 | ||
| Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance | Q24329133 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| An overview of the c-MET signaling pathway | Q24633986 | ||
| HIF-1: upstream and downstream of cancer metabolism | Q24647482 | ||
| Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer | Q24652941 | ||
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast | Q24685857 | ||
| Targeting HIF-1 for cancer therapy | Q27860504 | ||
| Epithelial-mesenchymal transitions in development and disease | Q27860630 | ||
| Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains | Q28114920 | ||
| HIF-1: mediator of physiological and pathophysiological responses to hypoxia | Q28140835 | ||
| Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Evaluation of HIF-1 inhibitors as anticancer agents | Q28253053 | ||
| The Met tyrosine kinase receptor in development and cancer | Q28263626 | ||
| Lysyl oxidase mediates hypoxic control of metastasis | Q28271667 | ||
| Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression | Q28272474 | ||
| Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group | Q28282755 | ||
| Hypoxia in cancer: significance and impact on clinical outcome | Q28298305 | ||
| HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia | Q28300406 | ||
| Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics | Q29615944 | ||
| TGF-beta and epithelial-to-mesenchymal transitions | Q29616456 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| The extracellular matrix: a dynamic niche in cancer progression | Q29617793 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance | Q29620462 | ||
| Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity | Q33224552 | ||
| PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours | Q33404024 | ||
| Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab | Q33418562 | ||
| Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol | Q33691999 | ||
| Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. | Q33827053 | ||
| Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. | Q33916081 | ||
| Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin | Q34018372 | ||
| The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 | Q34097892 | ||
| Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells | Q34152742 | ||
| DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability | Q34164868 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 | ||
| Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells | Q34348322 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity | Q34592273 | ||
| VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
| The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness | Q34885299 | ||
| Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors | Q35146269 | ||
| Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. | Q35202899 | ||
| Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2 | Q35273305 | ||
| Fatty acid synthase as a potential therapeutic target in cancer | Q35401716 | ||
| The MRP family of drug efflux pumps | Q35567296 | ||
| HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks | Q35749374 | ||
| The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis | Q35903445 | ||
| Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer | Q35928801 | ||
| Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer | Q36044487 | ||
| VHL: a very hip ligase | Q36182969 | ||
| The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival | Q36255823 | ||
| Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. | Q36289917 | ||
| Emerging roles of PKM2 in cell metabolism and cancer progression | Q36303571 | ||
| VEGF as a key mediator of angiogenesis in cancer | Q36319024 | ||
| Lasting longer without oxygen: The influence of hypoxia on Notch signaling | Q36336491 | ||
| EO9 (Apaziquone): from the clinic to the laboratory and back again | Q36603159 | ||
| Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts | Q36760417 | ||
| Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment | Q36794370 | ||
| Hypoxia: a key regulator of angiogenesis in cancer | Q36866153 | ||
| The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance | Q36890663 | ||
| Collagen prolyl hydroxylases are essential for breast cancer metastasis | Q36906597 | ||
| Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation | Q36907156 | ||
| Hypoxia and cancer | Q37008506 | ||
| Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance | Q37011260 | ||
| Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. | Q37084096 | ||
| Dysfunctional homologous recombination mediates genomic instability and progression in myeloma | Q37119930 | ||
| Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer | Q37145875 | ||
| Tirapazamine: from bench to clinical trials. | Q37230218 | ||
| Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development | Q37287417 | ||
| Regulation of cancer cell metabolism by hypoxia-inducible factor 1. | Q37359659 | ||
| Hypoxia-induced collagen synthesis of human lung fibroblasts by activating the angiotensin system | Q37420926 | ||
| HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs | Q37507008 | ||
| Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. | Q37573701 | ||
| Targeting the tumour vasculature: insights from physiological angiogenesis | Q37767356 | ||
| Hypoxia and hypoxia-inducible factors: master regulators of metastasis | Q37801762 | ||
| EMT: a new vision of hypoxia promoting cancer progression | Q37851315 | ||
| Lipid metabolism in cancer | Q38012542 | ||
| Regulation of EMT by TGFβ in cancer. | Q38019712 | ||
| Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia | Q38120850 | ||
| Targeting the ERBB family in cancer: couples therapy | Q38129286 | ||
| Targeting lactate metabolism for cancer therapeutics | Q38133722 | ||
| Tumor hypoxia as a driving force in genetic instability. | Q38155002 | ||
| Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways | Q38184665 | ||
| Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. | Q38369648 | ||
| Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors | Q39051622 | ||
| Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line | Q39169189 | ||
| A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. | Q39332797 | ||
| Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. | Q39425368 | ||
| Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis | Q39652705 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | 253-64 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Cancer Management and Research | Q5031417 |
| P1476 | title | Progress toward overcoming hypoxia-induced resistance to solid tumor therapy | |
| P478 | volume | 7 |
| Q92422527 | Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression |
| Q95267825 | Circular RNA circNRIP1 Sponges microRNA-138-5p to Maintain Hypoxia-Induced Resistance to 5-Fluorouracil Through HIF-1α-Dependent Glucose Metabolism in Gastric Carcinoma |
| Q37690276 | Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers |
| Q36674083 | Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells |
| Q39002822 | Hypoxia: A Double-Edged Sword in Cancer Therapy |
| Q55642634 | Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy. |
| Q46073141 | Inhibition of histone/lysine acetyltransferase activity kills CoCl2-treated and hypoxia-exposed gastric cancer cells and reduces their invasiveness |
| Q38769076 | JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy |
| Q90481661 | One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy |
| Q55287028 | Preoperative Ultrasonographic Evaluation for Malignancy of Soft-Tissue Sarcoma: A Retrospective Study. |
| Q38757793 | Selective GPR55 antagonism reduces chemoresistance in cancer cells |
| Q26774750 | Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs |
| Q92190787 | The Extracellular, Cellular, and Nuclear Stiffness, a Trinity in the Cancer Resistome-A Review |
| Q57107650 | The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis |
| Q50133464 | The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: A theoretical and experimental study. |
Search more.